Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amrubicin Monotherapy or Combination vs Etoposide-Cisplatin in ES-SCLC
NCT00388960Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2006
- Primary completion
- Apr 2010
- Modality
- DNA Intercalators/Alkylators
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of amrubicin in small cell lung cancer (SCLC) (3 arms), sponsored by Celgene Corporation. Primary endpoint: Objective Tumor Response Rate. Started Nov 2006; status: completed.
02
Drugs
amrubicin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00388960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00388960.